Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context
Summary: Background: Despite progress in the treatment of Waldenström macroglobulinaemia, this disease still remains a therapeutic challenge, especially in older patients with multiple comorbidities. This study aimed to assess obinutuzumab single-agent induction and maintenance activity and safety...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | EClinicalMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537025003153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731249006968832 |
|---|---|
| author | Tomasz Wróbel Elżbieta Kalicińska Jan Maciej Zaucha Marta Morawska Krzysztof Giannopoulos Krzysztof Jamroziak Ewa Lech-Marańda Michał Taszner Agnieszka Szeremet Bartosz Małecki Agnieszka Druzd-Sitek Anna Łojko-Dankowska Dominik Dytfeld |
| author_facet | Tomasz Wróbel Elżbieta Kalicińska Jan Maciej Zaucha Marta Morawska Krzysztof Giannopoulos Krzysztof Jamroziak Ewa Lech-Marańda Michał Taszner Agnieszka Szeremet Bartosz Małecki Agnieszka Druzd-Sitek Anna Łojko-Dankowska Dominik Dytfeld |
| author_sort | Tomasz Wróbel |
| collection | DOAJ |
| description | Summary: Background: Despite progress in the treatment of Waldenström macroglobulinaemia, this disease still remains a therapeutic challenge, especially in older patients with multiple comorbidities. This study aimed to assess obinutuzumab single-agent induction and maintenance activity and safety in patients with relapsed or refractory Waldenström macroglobulinaemia. Methods: This open-label, single-arm phase 2 study enrolled patients with relapsed or refractory Waldenström macroglobulinaemia with confirmed CD20 expression and measurable disease. Patients received an infusion of obinutuzumab 1000 mg on days 1, 8, and 15 during first cycle, followed by five more cycles with infusions on day 1. Patients with a response defined as stable disease or better at the end of the induction phase entered 2-year maintenance treatment with obinutuzumab 1000 mg every eight weeks, followed by the observation phase. The primary endpoint was best overall response. This trial is registered at ClinicalTrials.gov, NCT03679455, and EudraCT, 2016-005053-20. Findings: Between September 04, 2018 and March 25, 2021, we enrolled 23 patients (median age 66 years, range 52–86 years). The median duration of follow-up was 3.8 years (range 0.1–6.0).The best overall response rate (BOR) was 65.2% (15 of 23 [95% CI 42.7–83.6]). In patients with baseline IgM level ≥40 g/L, BOR was reported in 75.0% (9 of 12 [95% CI 42.8–90.5]).Overall response rate (ORR) at the end of induction was reported in 12 (51%) of 23 patients. At the end of the study, ORR was reported in 15 (65%) of 23 patients. After the end of the study, the percentage of patients who achieved a very good partial response (VGPR) and complete remission (CR) has increased significantly compared to proportion of patients who achieved VGPR and CR after the 6-month induction phase (26% vs 4%, and 4% vs 0%, respectively). Progression-free survival was 65% (95% CI 43–84); overall survival was 74% (95% CI 52–90).Grade 3 or higher adverse events occurred in 15 (65.2%) patients, however, treatment-related grade 3 or higher adverse events occurred in 8 (34.8%) patients. One death that occurred during the induction phase was associated to disease progression, one death that occurred during maintenance phase was related to COVID-19, and one with disease progression. The remaining 3 deaths occurred during the follow-up phase, during subsequent lines of treatment. Interpretation: Obinutuzumab is active as single-agent induction and maintenance in patients with relapsed or refractory Waldenström macroglobulinaemia with manageable toxicity. Clinically significant is the fact that very good responses were deepened after the completion of the study with obinutuzumab. Funding: Roche Polska Ltd. |
| format | Article |
| id | doaj-art-9575ac5d65b141d9bf3a31fedfb1578f |
| institution | DOAJ |
| issn | 2589-5370 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj-art-9575ac5d65b141d9bf3a31fedfb1578f2025-08-20T03:08:36ZengElsevierEClinicalMedicine2589-53702025-08-018610338310.1016/j.eclinm.2025.103383Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in contextTomasz Wróbel0Elżbieta Kalicińska1Jan Maciej Zaucha2Marta Morawska3Krzysztof Giannopoulos4Krzysztof Jamroziak5Ewa Lech-Marańda6Michał Taszner7Agnieszka Szeremet8Bartosz Małecki9Agnieszka Druzd-Sitek10Anna Łojko-Dankowska11Dominik Dytfeld12Wrocław Medical University, Wrocław, Poland; Corresponding author. Wrocław Medical University, Wybrzeże L. Pasteura 4, Wrocław, 50-367, Poland.Wrocław Medical University, Wrocław, PolandMedical University of Gdańsk, Gdańsk, PolandMedical University of Lublin, Lublin, PolandMedical University of Lublin, Lublin, PolandMedical University of Warsaw, Warsaw, PolandInstitute of Hematology and Blood Transfusion, Warsaw, PolandInstitute of Hematology and Blood Transfusion, Warsaw, PolandWrocław Medical University, Wrocław, PolandPoznań University of Medical Sciences, Poznań, PolandMaria Sklodowska-Curie National Research Institute of Oncology, PolandPoznań University of Medical Sciences, Poznań, PolandPoznań University of Medical Sciences, Poznań, PolandSummary: Background: Despite progress in the treatment of Waldenström macroglobulinaemia, this disease still remains a therapeutic challenge, especially in older patients with multiple comorbidities. This study aimed to assess obinutuzumab single-agent induction and maintenance activity and safety in patients with relapsed or refractory Waldenström macroglobulinaemia. Methods: This open-label, single-arm phase 2 study enrolled patients with relapsed or refractory Waldenström macroglobulinaemia with confirmed CD20 expression and measurable disease. Patients received an infusion of obinutuzumab 1000 mg on days 1, 8, and 15 during first cycle, followed by five more cycles with infusions on day 1. Patients with a response defined as stable disease or better at the end of the induction phase entered 2-year maintenance treatment with obinutuzumab 1000 mg every eight weeks, followed by the observation phase. The primary endpoint was best overall response. This trial is registered at ClinicalTrials.gov, NCT03679455, and EudraCT, 2016-005053-20. Findings: Between September 04, 2018 and March 25, 2021, we enrolled 23 patients (median age 66 years, range 52–86 years). The median duration of follow-up was 3.8 years (range 0.1–6.0).The best overall response rate (BOR) was 65.2% (15 of 23 [95% CI 42.7–83.6]). In patients with baseline IgM level ≥40 g/L, BOR was reported in 75.0% (9 of 12 [95% CI 42.8–90.5]).Overall response rate (ORR) at the end of induction was reported in 12 (51%) of 23 patients. At the end of the study, ORR was reported in 15 (65%) of 23 patients. After the end of the study, the percentage of patients who achieved a very good partial response (VGPR) and complete remission (CR) has increased significantly compared to proportion of patients who achieved VGPR and CR after the 6-month induction phase (26% vs 4%, and 4% vs 0%, respectively). Progression-free survival was 65% (95% CI 43–84); overall survival was 74% (95% CI 52–90).Grade 3 or higher adverse events occurred in 15 (65.2%) patients, however, treatment-related grade 3 or higher adverse events occurred in 8 (34.8%) patients. One death that occurred during the induction phase was associated to disease progression, one death that occurred during maintenance phase was related to COVID-19, and one with disease progression. The remaining 3 deaths occurred during the follow-up phase, during subsequent lines of treatment. Interpretation: Obinutuzumab is active as single-agent induction and maintenance in patients with relapsed or refractory Waldenström macroglobulinaemia with manageable toxicity. Clinically significant is the fact that very good responses were deepened after the completion of the study with obinutuzumab. Funding: Roche Polska Ltd.http://www.sciencedirect.com/science/article/pii/S2589537025003153Waldenström macroglobulinaemiaObinutuzumab monotherapyImmunotherapyCD20 antibodyLymphoplasmacytic lymphoma |
| spellingShingle | Tomasz Wróbel Elżbieta Kalicińska Jan Maciej Zaucha Marta Morawska Krzysztof Giannopoulos Krzysztof Jamroziak Ewa Lech-Marańda Michał Taszner Agnieszka Szeremet Bartosz Małecki Agnieszka Druzd-Sitek Anna Łojko-Dankowska Dominik Dytfeld Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context EClinicalMedicine Waldenström macroglobulinaemia Obinutuzumab monotherapy Immunotherapy CD20 antibody Lymphoplasmacytic lymphoma |
| title | Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context |
| title_full | Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context |
| title_fullStr | Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context |
| title_full_unstemmed | Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context |
| title_short | Obinutuzumab induction and maintenance in patients with Waldenström macroglobulinaemia: an open-label, single-arm phase 2 studyResearch in context |
| title_sort | obinutuzumab induction and maintenance in patients with waldenstrom macroglobulinaemia an open label single arm phase 2 studyresearch in context |
| topic | Waldenström macroglobulinaemia Obinutuzumab monotherapy Immunotherapy CD20 antibody Lymphoplasmacytic lymphoma |
| url | http://www.sciencedirect.com/science/article/pii/S2589537025003153 |
| work_keys_str_mv | AT tomaszwrobel obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT elzbietakalicinska obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT janmaciejzaucha obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT martamorawska obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT krzysztofgiannopoulos obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT krzysztofjamroziak obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT ewalechmaranda obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT michałtaszner obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT agnieszkaszeremet obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT bartoszmałecki obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT agnieszkadruzdsitek obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT annałojkodankowska obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext AT dominikdytfeld obinutuzumabinductionandmaintenanceinpatientswithwaldenstrommacroglobulinaemiaanopenlabelsinglearmphase2studyresearchincontext |